# OnCo record nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "nsclc" ;
  schema:name "Non-small-cell lung cancer"@en ;
  schema:alternateName "LUAD"@en, "LUSC"@en, "LSCC"@en, "TCGA-LUAD"@en, "TCGA-LUSC"@en, "lung adenocarcinoma (TCGA LUAD cohort)"@en, "lung squamous cell carcinoma (TCGA LUSC and CPTAC LSCC cohorts)"@en, "Non-small-cell lung cancer (adenocarcinoma, squamous, large cell)"@en, "NSCLC"@en, "Non-small cell lung carcinoma"@en, "Non-small-cell carcinoma of the lung"@en ;
  schema:description "Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."@en ;
  schema:url <https://onco.cc/cancers/nsclc/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Non-small-cell_lung_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q3658562> ;
  schema:citation <https://en.wikipedia.org/wiki/Non-small-cell_lung_cancer>, <https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf>, <https://seer.cancer.gov/statfacts/html/lungb.html>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/incidence>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/mortality>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/survival>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/risk-factors>, <https://www.nhs.uk/conditions/lung-cancer/>, <https://www.nhs.uk/conditions/lung-cancer/symptoms/>, <https://www.nhs.uk/tests-and-treatments/lung-cancer-screening/>, <https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer>, <https://www.nice.org.uk/guidance/ng122/chapter/Diagnosis-and-staging>, <https://www.nice.org.uk/guidance/ng209>, <https://view-health-screening-recommendations.service.gov.uk/lung-cancer/>, <https://www.gov.uk/government/news/new-lung-cancer-screening-roll-out-to-detect-cancer-sooner>, <https://doi.org/10.1056/nejmoa1102873>, <https://doi.org/10.1056/nejmoa1911793>, <https://doi.org/10.1001/jama.2021.1117>, <https://doi.org/10.1001/jama.2021.0377>, <https://doi.org/10.1038/s41591-026-04292-y>, <https://doi.org/10.31083/bjhm53142>, <https://doi.org/10.1038/s41416-021-01278-0>, <https://doi.org/10.1016/j.canep.2023.102354>, <https://doi.org/10.1093/bjr/tqaf161>, <https://doi.org/10.1016/j.jtho.2024.02.011>, <https://doi.org/10.1016/j.jtho.2023.12.006>, <https://doi.org/10.1016/j.jtho.2024.01.019>, <https://doi.org/10.1016/j.jtho.2023.01.088>, <https://doi.org/10.1002/ijc.70561>, <https://doi.org/10.1016/j.jtho.2021.11.003>, <https://doi.org/10.1016/s2213-2600(24)00428-4>, <https://doi.org/10.1038/s44276-023-00006-w>, <https://doi.org/10.1136/bmjresp-2025-003966>, <https://doi.org/10.1002/ijc.30084>, <https://doi.org/10.1002/hsr2.73080>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11163648/>, <https://www.nhs.uk/conditions/lung-cancer/treatment/>, <https://www.nice.org.uk/guidance/ng122/chapter/Palliative-interventions-and-supportive-and-palliative-care>, <https://www.nice.org.uk/guidance/ng122/chapter/Support-from-clinical-nurse-specialists>, <https://www.nice.org.uk/guidance/ng122/chapter/Follow-up-and-patient-perspectives>, <https://roycastle.org/learn-about-lung-cancer/living-with-cancer/>, <https://roycastle.org/our-support/>, <https://www.macmillan.org.uk/cancer-information-and-support/lung-cancer/non-small-cell-lung-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/breathlessness>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/superior-vena-cava-obstruction>, <https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with>, <https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/coping-with-breathlessness>, <https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/coping>, <https://www.cancerresearchuk.org/about-cancer/coping/physically/breathing-problems/fluid-on-lungs-pleural-effusion>, <https://www.asthmaandlung.org.uk/symptoms-tests-treatments/symptoms/breathlessness>, <https://www.maggies.org/support-and-information/>, <https://www.mariecurie.org.uk/information/getting-care/palliative-care>, <https://doi.org/10.1056/NEJMoa1000678>, <https://www.natcan.org.uk/wp-content/uploads/2026/02/NLCA-State-of-the-Nation-Report-2026.pdf>, <https://rmpartners.nhs.uk/wp-content/uploads/2024/09/national-optimal-lung-cancer-pathway_v4_01jan2024.pdf>, <https://roycastle.org/> ;
  onco:tag "lung", "spike" ;
  onco:related <https://onco.cc/cancers/sclc/>, <https://onco.cc/roadmaps/kras-roadmap/>, <https://onco.cc/roadmaps/adc-generations/>, <https://onco.cc/roadmaps/immunotherapy-roadmap/>, <https://onco.cc/pairings/targeted-before-io-nsclc/>, <https://onco.cc/pairings/amivantamab-plus-lazertinib/>, <https://onco.cc/pairings/tki-then-adc-lung/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/lung-lcnec/>, <https://onco.cc/biomarkers/pd-l1-tps/>, <https://onco.cc/biomarkers/pd-l1-tc-score/>, <https://onco.cc/biomarkers/pd-l1-ic-score/>, <https://onco.cc/biomarkers/egfr-exon-19-deletion/>, <https://onco.cc/biomarkers/egfr-l858r/>, <https://onco.cc/biomarkers/egfr-exon-20-insertion/>, <https://onco.cc/biomarkers/egfr-t790m/>, <https://onco.cc/biomarkers/egfr-c797s/>, <https://onco.cc/biomarkers/alk-fusion/>, <https://onco.cc/biomarkers/alk-resistance-mutation/>, <https://onco.cc/biomarkers/ros1-fusion/>, <https://onco.cc/biomarkers/ret-fusion/>, <https://onco.cc/biomarkers/met-ex14/>, <https://onco.cc/biomarkers/met-amplification-readout/>, <https://onco.cc/biomarkers/met-overexpression/>, <https://onco.cc/biomarkers/her2-mutation/>, <https://onco.cc/biomarkers/kras-g12c/>, <https://onco.cc/biomarkers/kras-g12d/>, <https://onco.cc/biomarkers/braf-v600e/>, <https://onco.cc/biomarkers/braf-class-ii-iii/>, <https://onco.cc/biomarkers/ntrk-fusion/>, <https://onco.cc/biomarkers/nrg1-fusion/>, <https://onco.cc/biomarkers/stk11-keap1-loss/>, <https://onco.cc/biomarkers/tmb-high/>, <https://onco.cc/biomarkers/pik3ca-hotspot-mutation/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/omega3-epa-cachexia/>, <https://onco.cc/technologies/shark-cartilage/>, <https://onco.cc/technologies/hydrazine-sulfate/>, <https://onco.cc/technologies/nhs-targeted-lung-health-check/>, <https://onco.cc/technologies/low-dose-ct-screening/>, <https://onco.cc/technologies/robotic-bronchoscopy/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/pet/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/pain-management/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/tmb-testing/>, <https://onco.cc/technologies/rna-seq/>, <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/technologies/cytogenetics-fish/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/ret/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/stk11/>, <https://onco.cc/targets/keap1/>, <https://onco.cc/targets/nrg1/>, <https://onco.cc/targets/smarca4/>, <https://onco.cc/targets/rbm10/>, <https://onco.cc/targets/nf1/>, <https://onco.cc/targets/cdkn2a/>, <https://onco.cc/targets/nkx2-1/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/nfe2l2/>, <https://onco.cc/targets/sox2/>, <https://onco.cc/targets/fgfr1/> ;
  onco:drugs <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/drugs/oncomine-dx-target-test/>, <https://onco.cc/drugs/therascreen-cdx/>, <https://onco.cc/drugs/ventana-pd-l1-sp142/>, <https://onco.cc/drugs/caris-mi-cancer-seek/>, <https://onco.cc/drugs/resolution-ctdx-first/>, <https://onco.cc/drugs/necitumumab/>, <https://onco.cc/drugs/talc-sclerosant/>, <https://onco.cc/drugs/samarium-153-lexidronam/> ;
  onco:companies <https://onco.cc/companies/kanvas-biosciences/>, <https://onco.cc/companies/nanjing-leads-biolabs/>, <https://onco.cc/companies/avistone-biotechnology/>, <https://onco.cc/companies/catalym/>, <https://onco.cc/companies/shanghai-fosun-pharmaceutical-industrial-development/>, <https://onco.cc/companies/bioinvent-international/>, <https://onco.cc/companies/haihe-biopharma/>, <https://onco.cc/companies/multitude-therapeutics/>, <https://onco.cc/companies/orion-orion-pharma/>, <https://onco.cc/companies/epicentrx/>, <https://onco.cc/companies/shenzhen-ionova-life-sciences/>, <https://onco.cc/companies/ap-biosciences/>, <https://onco.cc/companies/celltrion/>, <https://onco.cc/companies/civatech-oncology/>, <https://onco.cc/companies/elpiscience-suzhou-biopharma/>, <https://onco.cc/companies/genprex/>, <https://onco.cc/companies/ionctura/>, <https://onco.cc/companies/krystal-biotech/>, <https://onco.cc/companies/mabxience-research-s-l/>, <https://onco.cc/companies/maia-biotechnology/>, <https://onco.cc/companies/mbrace-therapeutics/>, <https://onco.cc/companies/molecular-partners/>, <https://onco.cc/companies/stcube/>, <https://onco.cc/companies/vyriad/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/boehringer-ingelheim/>, <https://onco.cc/companies/nuvalent/>, <https://onco.cc/companies/akeso/>, <https://onco.cc/companies/summit-therapeutics/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/daiichi-sankyo/> ;
  onco:institutions <https://onco.cc/institutions/roy-castle-lung-cancer-foundation/>, <https://onco.cc/institutions/royal-papworth/>, <https://onco.cc/institutions/liverpool-heart-and-chest/>, <https://onco.cc/institutions/leeds-cancer-centre/>, <https://onco.cc/institutions/birmingham-cancer-centre/>, <https://onco.cc/institutions/uclh/>, <https://onco.cc/institutions/the-christie/>, <https://onco.cc/institutions/royal-marsden/>, <https://onco.cc/institutions/newcastle-cancer-centre/>, <https://onco.cc/institutions/nottingham-cancer-centre/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/sclc-signalling/>, <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/keap1-nrf2/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/fgfr-signalling/>, <https://onco.cc/pathways/swi-snf-chromatin/>, <https://onco.cc/pathways/notch/>, <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/>, <https://onco.cc/pathways/t-cell-exhaustion/>, <https://onco.cc/pathways/mutagenesis-signatures/>, <https://onco.cc/pathways/chromosomal-instability/>, <https://onco.cc/pathways/clonal-evolution/>, <https://onco.cc/pathways/resistance-routes-map/>, <https://onco.cc/pathways/drug-tolerant-persisters/>, <https://onco.cc/pathways/myc/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/>, <https://onco.cc/pathways/cancer-immunity-cycle/>, <https://onco.cc/pathways/chemical-carcinogenesis-receptor-activation/> ;
  onco:terms <https://onco.cc/terms/tps/>, <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/terms/egfr-exon20-insertion/>, <https://onco.cc/terms/c797s/>, <https://onco.cc/terms/met-amplification/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/oligoprogression/>, <https://onco.cc/terms/histology/>, <https://onco.cc/terms/pack-year/>, <https://onco.cc/terms/never-smoker-lung-cancer/>, <https://onco.cc/terms/ebus-tbna/>, <https://onco.cc/terms/tnm-9-lung-cancer/>, <https://onco.cc/terms/resectability-lung-cancer/>, <https://onco.cc/terms/pneumonitis/>, <https://onco.cc/terms/pulmonary-nodule/>, <https://onco.cc/terms/lung-rads/>, <https://onco.cc/terms/radon/>, <https://onco.cc/terms/asbestos/>, <https://onco.cc/terms/smoking-cessation/>, <https://onco.cc/terms/haemoptysis/>, <https://onco.cc/terms/pancoast-tumour/>, <https://onco.cc/terms/spread-through-air-spaces/>, <https://onco.cc/terms/ttf1-p40/>, <https://onco.cc/terms/mediastinal-lymph-node-stations/>, <https://onco.cc/terms/targeted-lung-health-check/>, <https://onco.cc/terms/oligometastatic/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/tnm-staging/>, <https://onco.cc/terms/bronchoscopy/>, <https://onco.cc/terms/malignant-pleural-effusion/>, <https://onco.cc/terms/superior-vena-cava-obstruction/>, <https://onco.cc/terms/sublobar-resection/>, <https://onco.cc/terms/lobectomy/>, <https://onco.cc/terms/segmentectomy/>, <https://onco.cc/terms/pneumonectomy/>, <https://onco.cc/terms/radiation-pneumonitis/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/immune-colitis/>, <https://onco.cc/terms/pleural-effusion/>, <https://onco.cc/terms/pleurodesis/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/bone-metastases/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/anaemia/>, <https://onco.cc/terms/cachexia/>, <https://onco.cc/terms/curative-intent/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/egfr-mutation-subtypes/>, <https://onco.cc/terms/kras-mutation-subtypes/>, <https://onco.cc/terms/met-exon-14-skipping/>, <https://onco.cc/terms/stk11-keap1/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/gene-amplification/>, <https://onco.cc/terms/amplification/>, <https://onco.cc/terms/copy-number-variation-term/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/cross-resistance/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/wild-type/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/mutational-signature/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/immune-exclusion/>, <https://onco.cc/terms/neoantigen/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/fish/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/cfdna/>, <https://onco.cc/terms/biopsy/>, <https://onco.cc/terms/somatic-mutations-wxs-wgs/>, <https://onco.cc/terms/vus/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/cdkn2a-homozygous-deletion/>, <https://onco.cc/terms/braf-v600-mutation/>, <https://onco.cc/terms/tert-promoter/> ;
  onco:trials <https://onco.cc/trials/gefitinib-chemo-tmh/>, <https://onco.cc/trials/symbiotic-lung-04/>, <https://onco.cc/trials/symbiotic-lung-01/>, <https://onco.cc/trials/nct06980272/>, <https://onco.cc/trials/nct06612151/>, <https://onco.cc/trials/nct07739758/>, <https://onco.cc/trials/nct06616532/>, <https://onco.cc/trials/nct07174908/>, <https://onco.cc/trials/nct07155187/>, <https://onco.cc/trials/nct07005102/>, <https://onco.cc/trials/nct05211895/>, <https://onco.cc/trials/nct05502237/>, <https://onco.cc/trials/nct05020769/>, <https://onco.cc/trials/nct05221840/>, <https://onco.cc/trials/nct06498479/>, <https://onco.cc/trials/nct07189455/>, <https://onco.cc/trials/nct07554339/>, <https://onco.cc/trials/nct06345729/>, <https://onco.cc/trials/nct07431827/>, <https://onco.cc/trials/nct07190248/>, <https://onco.cc/trials/nct06954246/>, <https://onco.cc/trials/nsclc-2/>, <https://onco.cc/trials/nct05450692/>, <https://onco.cc/trials/sqnsclc/>, <https://onco.cc/trials/nct07416994/>, <https://onco.cc/trials/nct05132075/>, <https://onco.cc/trials/nct05487391/>, <https://onco.cc/trials/nct05690945/>, <https://onco.cc/trials/nct07063745/>, <https://onco.cc/trials/nct06247605/>, <https://onco.cc/trials/nct07459751/>, <https://onco.cc/trials/nct06927986/>, <https://onco.cc/trials/nct07365319/>, <https://onco.cc/trials/nct07668752/>, <https://onco.cc/trials/nct05973773/>, <https://onco.cc/trials/nct07128199/>, <https://onco.cc/trials/aurora/>, <https://onco.cc/trials/nct06754644/>, <https://onco.cc/trials/nct05671510/>, <https://onco.cc/trials/dllevate/>, <https://onco.cc/trials/nct06671379/>, <https://onco.cc/trials/nct07365241/>, <https://onco.cc/trials/fleteo/>, <https://onco.cc/trials/nsclc-3/>, <https://onco.cc/trials/nct06984588/>, <https://onco.cc/trials/nct06416410/>, <https://onco.cc/trials/nct06735391/>, <https://onco.cc/trials/nct06635824/>, <https://onco.cc/trials/nct04655976/>, <https://onco.cc/trials/nct07566052/>, <https://onco.cc/trials/nct07662395/>, <https://onco.cc/trials/nct07217301/>, <https://onco.cc/trials/nct06646276/>, <https://onco.cc/trials/nct07362459/>, <https://onco.cc/trials/nct06472245/>, <https://onco.cc/trials/nsclc-4/>, <https://onco.cc/trials/nct06417008/>, <https://onco.cc/trials/nct06080776/>, <https://onco.cc/trials/nct06123754/>, <https://onco.cc/trials/luminosity/>, <https://onco.cc/trials/jcog0403/>, <https://onco.cc/trials/chisel/>, <https://onco.cc/trials/nct06712316/>, <https://onco.cc/trials/nct05687266/>, <https://onco.cc/trials/nct02486718/>, <https://onco.cc/trials/nct06119581/>, <https://onco.cc/trials/nct03164616/>, <https://onco.cc/trials/nct05555732/>, <https://onco.cc/trials/nct06627647/>, <https://onco.cc/trials/nct06692738/>, <https://onco.cc/trials/nct02453282/>, <https://onco.cc/trials/nct03178552/>, <https://onco.cc/trials/nct06561386/>, <https://onco.cc/trials/nct02542293/>, <https://onco.cc/trials/nct05984277/>, <https://onco.cc/trials/nct07513376/>, <https://onco.cc/trials/nct04380636/>, <https://onco.cc/trials/nct06077760/>, <https://onco.cc/trials/nct06422143/>, <https://onco.cc/trials/nct07361497/>, <https://onco.cc/trials/nct06868277/>, <https://onco.cc/trials/nct03800134/>, <https://onco.cc/trials/nct06312137/>, <https://onco.cc/trials/nct06767514/>, <https://onco.cc/trials/nct04988295/>, <https://onco.cc/trials/nct06012435/>, <https://onco.cc/trials/nct06726265/>, <https://onco.cc/trials/nct05920356/>, <https://onco.cc/trials/nct07361510/>, <https://onco.cc/trials/nct06417814/>, <https://onco.cc/trials/nct05215340/>, <https://onco.cc/trials/nct06216301/>, <https://onco.cc/trials/nct06687369/>, <https://onco.cc/trials/nct03833154/>, <https://onco.cc/trials/nct06838273/>, <https://onco.cc/trials/nct06758401/>, <https://onco.cc/trials/nct06890598/>, <https://onco.cc/trials/nct06382129/>, <https://onco.cc/trials/nct06899126/>, <https://onco.cc/trials/nct06623422/>, <https://onco.cc/trials/nct06357533/>, <https://onco.cc/trials/nct03003962/>, <https://onco.cc/trials/nct03390686/>, <https://onco.cc/trials/nct06875310/>, <https://onco.cc/trials/nct04613596/>, <https://onco.cc/trials/nct04923906/>, <https://onco.cc/trials/nct05654454/>, <https://onco.cc/trials/nct05609968/>, <https://onco.cc/trials/nct06170788/>, <https://onco.cc/trials/nct05089734/>, <https://onco.cc/trials/nct05987956/>, <https://onco.cc/trials/nct06793215/>, <https://onco.cc/trials/nct06881784/>, <https://onco.cc/trials/nct06350097/>, <https://onco.cc/trials/nct07183189/>, <https://onco.cc/trials/nct06041776/>, <https://onco.cc/trials/nct06617416/>, <https://onco.cc/trials/ukls/>, <https://onco.cc/trials/ylst/>, <https://onco.cc/trials/summit-lung/>, <https://onco.cc/trials/lungsearch/>, <https://onco.cc/trials/chart-lung/>, <https://onco.cc/trials/big-lung-trial/>, <https://onco.cc/trials/violet/>, <https://onco.cc/trials/tracerx/> ;
  onco:people <https://onco.cc/people/philip-crosbie/>, <https://onco.cc/people/matthew-callister/>, <https://onco.cc/people/john-field/>, <https://onco.cc/people/david-baldwin/>, <https://onco.cc/people/gary-middleton/>, <https://onco.cc/people/sanjay-popat/>, <https://onco.cc/people/alastair-greystoke/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/>, <https://onco.cc/key-papers/paper-tcga-lung-squamous-nature-2012/>, <https://onco.cc/key-papers/paper-campbell-pan-lung-somatic-alterations-nat-genet-2016/>, <https://onco.cc/key-papers/paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017/>, <https://onco.cc/key-papers/paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020/>, <https://onco.cc/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/>, <https://onco.cc/key-papers/paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016/>, <https://onco.cc/key-papers/paper-soda-eml4-alk-fusion-nature-2007/>, <https://onco.cc/key-papers/paper-bergethon-ros1-rearrangements-lung-jco-2012/>, <https://onco.cc/key-papers/paper-awad-met-exon-14-mutations-lung-jco-2016/>, <https://onco.cc/key-papers/paper-weiss-fgfr1-amplification-squamous-lung-sci-transl-med-2010/>, <https://onco.cc/key-papers/paper-fernandez-cuesta-cd74-nrg1-fusion-lung-cancer-discov-2014/>, <https://onco.cc/key-papers/paper-jonna-nrg1-fusions-solid-tumours-ccr-2019/>, <https://onco.cc/key-papers/paper-schoenfeld-smarca4-alterations-lung-ccr-2020/>, <https://onco.cc/key-papers/paper-skoulidis-kras-co-mutation-subsets-cancer-discov-2015/>, <https://onco.cc/key-papers/paper-arbour-kras-co-mutation-outcomes-ccr-2018/>, <https://onco.cc/key-papers/paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022/>, <https://onco.cc/key-papers/paper-blueprint-phase-2-pd-l1-assays-jto-2018/>, <https://onco.cc/key-papers/paper-rimm-pd-l1-assay-comparison-jama-oncol-2017/>, <https://onco.cc/key-papers/paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018/>, <https://onco.cc/key-papers/paper-checkmate-026-first-line-nivolumab-nejm-2017/>, <https://onco.cc/key-papers/paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022/>, <https://onco.cc/key-papers/paper-keynote-042-tmb-mutations-ann-oncol-2023/>, <https://onco.cc/key-papers/paper-keynote-189-407-tmb-jtocrr-2023/>, <https://onco.cc/key-papers/paper-gandara-blood-tmb-atezolizumab-nat-med-2018/>, <https://onco.cc/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/>, <https://onco.cc/key-papers/paper-pao-egfr-t790m-acquired-resistance-plos-med-2005/>, <https://onco.cc/key-papers/paper-engelman-met-amplification-gefitinib-resistance-science-2007/>, <https://onco.cc/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/>, <https://onco.cc/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/>, <https://onco.cc/key-papers/paper-gainor-alk-resistance-mutations-cancer-discov-2016/>, <https://onco.cc/key-papers/paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019/>, <https://onco.cc/key-papers/paper-shaw-alk-l1198f-resensitisation-nejm-2016/>, <https://onco.cc/key-papers/paper-lee-clonal-history-small-cell-transformation-jco-2017/>, <https://onco.cc/key-papers/paper-offin-rb1-tp53-transformation-risk-jto-2019/>, <https://onco.cc/key-papers/paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019/>, <https://onco.cc/key-papers/paper-lindeman-lung-molecular-testing-guideline-jto-2018/>, <https://onco.cc/key-papers/paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019/>, <https://onco.cc/key-papers/paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019/>, <https://onco.cc/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/>, <https://onco.cc/key-papers/paper-gay-sclc-subtypes-inflamed-cancer-cell-2021/>, <https://onco.cc/key-papers/paper-baine-sclc-subtype-immunohistochemistry-jto-2020/>, <https://onco.cc/key-papers/paper-hirsch-j-thorac-oncol/>, <https://onco.cc/key-papers/paper-rizvi-mutational-landscape-pd1-science-2015/>, <https://onco.cc/key-papers/paper-checkmate-227-n-engl-j-med-2018/>, <https://onco.cc/key-papers/paper-keynote-024-nejm-2016/>, <https://onco.cc/key-papers/paper-keynote-010-lancet-2016/>, <https://onco.cc/key-papers/paper-thress-nat-med/>, <https://onco.cc/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/>, <https://onco.cc/key-papers/paper-frampton-met-exon-14-cancer-discov-2015/>, <https://onco.cc/key-papers/paper-kras-nsclc-cancer-discov-2018/>, <https://onco.cc/key-papers/paper-tracerx-100-nejm-2017/>, <https://onco.cc/key-papers/paper-george-sclc-genomic-profiles-nature-2015/>, <https://onco.cc/key-papers/paper-zhang-lung-cancer-never-smokers-nat-genet-2021/>, <https://onco.cc/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/> ;
  onco:journals <https://onco.cc/journals/clinical-lung-cancer/>, <https://onco.cc/journals/lung-cancer-journal/>, <https://onco.cc/journals/thoracic-cancer/>, <https://onco.cc/journals/chinese-journal-of-lung-cancer/> ;
  onco:pipeline <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/tilatamig-samrotecan/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/patritumab-deruxtecan/>, <https://onco.cc/drugs/intismeran-autogene/>, <https://onco.cc/drugs/zidesamtinib/>, <https://onco.cc/drugs/pf-08634404/>, <https://onco.cc/drugs/shr-8068/>, <https://onco.cc/drugs/yl201/>, <https://onco.cc/drugs/shr-a2102/>, <https://onco.cc/drugs/tqb2102/>, <https://onco.cc/drugs/pm8002/>, <https://onco.cc/drugs/in10018/>, <https://onco.cc/drugs/telisotuzumab-adizutecan/>, <https://onco.cc/drugs/domvanalimab/>, <https://onco.cc/drugs/si-b001/>, <https://onco.cc/drugs/oleclumab/>, <https://onco.cc/drugs/cetrelimab/>, <https://onco.cc/drugs/hs-20093/>, <https://onco.cc/drugs/zg006/>, <https://onco.cc/drugs/calderasib/>, <https://onco.cc/drugs/ak117/>, <https://onco.cc/drugs/qlc5508/>, <https://onco.cc/drugs/budigalimab/>, <https://onco.cc/drugs/ceralasertib/>, <https://onco.cc/drugs/rc148/>, <https://onco.cc/drugs/yl202/>, <https://onco.cc/drugs/livmoniplimab/>, <https://onco.cc/drugs/jdq443/>, <https://onco.cc/drugs/saruparib/>, <https://onco.cc/drugs/ql1706/>, <https://onco.cc/drugs/monalizumab/>, <https://onco.cc/drugs/navlimetostat/>, <https://onco.cc/drugs/al8326/>, <https://onco.cc/drugs/hlx43/>, <https://onco.cc/drugs/sys6010/>, <https://onco.cc/drugs/kl-a167/>, <https://onco.cc/drugs/quemliclustat/>, <https://onco.cc/drugs/eik1001/>, <https://onco.cc/drugs/gfh375/>, <https://onco.cc/drugs/zipalertinib/>, <https://onco.cc/drugs/aglatimagene-besadenovec/>, <https://onco.cc/drugs/ql2107/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/tqb2450/>, <https://onco.cc/drugs/zl-1310/>, <https://onco.cc/drugs/shr-a2009/>, <https://onco.cc/drugs/pf-07248144/>, <https://onco.cc/drugs/abbv-706/>, <https://onco.cc/drugs/ty-9591/>, <https://onco.cc/drugs/tgrx-326/>, <https://onco.cc/drugs/uliledlimab/>, <https://onco.cc/drugs/sitneprotafib/>, <https://onco.cc/drugs/jmt101/>, <https://onco.cc/drugs/acasunlimab/>, <https://onco.cc/drugs/bnt324/>, <https://onco.cc/drugs/cobolimab/>, <https://onco.cc/drugs/olvimulogene-nanivacirepvec/>, <https://onco.cc/drugs/setidegrasib/>, <https://onco.cc/drugs/sctb41/>, <https://onco.cc/drugs/tak-928/>, <https://onco.cc/drugs/atigotatug/>, <https://onco.cc/drugs/sctb14/>, <https://onco.cc/drugs/ose2101/>, <https://onco.cc/drugs/pf-08046054/>, <https://onco.cc/drugs/hs-20117/>, <https://onco.cc/drugs/ibi363/>, <https://onco.cc/drugs/vs-7375/>, <https://onco.cc/drugs/t3011/>, <https://onco.cc/drugs/tng462/>, <https://onco.cc/drugs/mcla-129/>, <https://onco.cc/drugs/tqb6411/>, <https://onco.cc/drugs/anvumetostat/>, <https://onco.cc/drugs/xnw27011/>, <https://onco.cc/drugs/hmbd-001/>, <https://onco.cc/drugs/ssgj-706/>, <https://onco.cc/drugs/ep0031/>, <https://onco.cc/drugs/absk061/>, <https://onco.cc/drugs/rilvegostomig/>, <https://onco.cc/drugs/mavrostobart/>, <https://onco.cc/drugs/hb0036/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/drugs/tri-611/>, <https://onco.cc/drugs/silevertinib/>, <https://onco.cc/drugs/palacaparib/>, <https://onco.cc/drugs/peluntamig/>, <https://onco.cc/drugs/tng456/>, <https://onco.cc/drugs/jyp0015/>, <https://onco.cc/drugs/hlx26/>, <https://onco.cc/drugs/ba3071/>, <https://onco.cc/drugs/env-501/>, <https://onco.cc/drugs/azd7789/>, <https://onco.cc/drugs/vrn110755/>, <https://onco.cc/drugs/dji136/>, <https://onco.cc/drugs/js111/>, <https://onco.cc/drugs/tng260/>, <https://onco.cc/drugs/au-007/>, <https://onco.cc/drugs/or502/>, <https://onco.cc/drugs/jmt203/>, <https://onco.cc/drugs/befotertinib/>, <https://onco.cc/drugs/lp-184/>, <https://onco.cc/drugs/upifitamab-rilsodotin/>, <https://onco.cc/drugs/vibostolimab/>, <https://onco.cc/drugs/boserolimab/>, <https://onco.cc/drugs/neladalkib/>, <https://onco.cc/trials/alkove-1/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/trials/krascendo-1/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/trials/harmoni-3/>, <https://onco.cc/trials/telimet-nsclc-01/>, <https://onco.cc/drugs/sevabertinib/>, <https://onco.cc/technologies/low-dose-ct-screening/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/radiology-ai-screening/>, <https://onco.cc/technologies/immuno-pet/> ;
  onco:standardOfCare <https://onco.cc/technologies/low-dose-ct-screening/>, <https://onco.cc/trials/nlst-nelson/>, <https://onco.cc/technologies/robotic-bronchoscopy/>, <https://onco.cc/technologies/radiology-ai-screening/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/trials/checkmate-816/>, <https://onco.cc/trials/keynote-671/>, <https://onco.cc/trials/adaura/>, <https://onco.cc/trials/alina/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/pacific/>, <https://onco.cc/trials/laura/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/trials/flaura2/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/>, <https://onco.cc/trials/mariposa/>, <https://onco.cc/pairings/amivantamab-plus-lazertinib/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/trials/tropion-lung05/>, <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/terms/c797s/>, <https://onco.cc/terms/met-amplification/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/terms/egfr-exon20-insertion/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/trials/crown/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/neladalkib/>, <https://onco.cc/trials/alkove-1/>, <https://onco.cc/terms/oligoprogression/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/zidesamtinib/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/trials/codebreak-200/>, <https://onco.cc/trials/krystal-12/>, <https://onco.cc/trials/krascendo-1/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/targets/braf/>, <https://onco.cc/drugs/capmatinib-tepotinib/>, <https://onco.cc/drugs/telisotuzumab-vedotin/>, <https://onco.cc/trials/telimet-nsclc-01/>, <https://onco.cc/targets/met/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/trials/libretto-431/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/targets/ret/>, <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/drugs/sevabertinib/>, <https://onco.cc/trials/soho-01/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/targets/her2/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/trials/harmoni-2/>, <https://onco.cc/terms/tps/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/pairings/pd1-plus-chemo-pdl1-low/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/trials/tropion-lung01/>, <https://onco.cc/trials/harmoni-3/> .